Showing results (261-270 of 501) with videos related to

Sort By:
Pageof 51
Cancer Research|April 7, 2019
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate CancerShangze Li, Ka-Wing Fong, Galina Gritsina, et al.
JNCI Cancer Spectrum|October 9, 2025
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancerWilliam S Chen, Abuzar Moradi Tuchayi, Ali Sabbagh, et al.
Neuro-Oncology|February 25, 2025
Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapyKatie Lin, Christopher Zou, Akane Hubbard, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate CancerNeil R Parikh, Eric M Chang, Nicholas G Nickols, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 19, 2020
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trialWolfgang P Fendler, Jeremie Calais, Matthias Eiber, et al.
Cancer|March 10, 2021
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancerDaniel H Kwon, Jonathan Chou, Steven M Yip, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
BJU International|July 16, 2017
Erectile function after stereotactic body radiotherapy for localized prostate cancerRobert T Dess, Holly E Hartman, Nima Aghdam, et al.
Molecular Cancer Research : MCR|February 18, 2018
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic SignatureUdit Singhal, Yugang Wang, James Henderson, et al.
Cancer|July 20, 2016
National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?Brandon A Mahal, Yu-Wei Chen, Vinayak Muralidhar, et al.
Pageof 51